Investment Rating - The report suggests a cautious subscription for the company [1] Core Insights - The company is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market, targeting affluent individuals with a disposable income exceeding RMB 200,000 [2] - The private mid-to-high-end healthcare service market in China is expected to grow significantly, with total revenue projected to increase from RMB 193 billion in 2020 to RMB 426 billion by 2024, reflecting a compound annual growth rate (CAGR) of 21.9% [3] - The company operates 19 healthcare facilities across major Chinese cities, including 17 clinics and 2 hospitals, and holds a market share of 2.0% in the private mid-to-high-end healthcare service sector [3] Financial Performance - The company's revenue for 2023 and 2024 is projected to be RMB 690 million and RMB 959 million, respectively, with a net profit of RMB 802 million expected in 2024 [4] - For the first eight months of 2025, the company has already achieved a revenue of RMB 696 million, representing a year-on-year growth of 14.0% [4] - The estimated market capitalization post-IPO is between HKD 37.15 billion and HKD 42.88 billion, with a price-to-earnings (PE) ratio of 26-31 times, indicating a relatively high valuation [4]